Revelation Biosciences reports positive Phase 1b Gemini results; plans Phase 2/3 AKI study in 2026

REVELATION BIOSCIENCES, INC.

Phase 1b CKD study completed with positive results; Gemini rebalances inflammation at cellular level.
CEO expects FDA meeting later in 2025 to discuss clinical/regulatory pathways for acute kidney injury.
Company plans to start Phase 2/3 AKI study in 2026, building manufacturing and CRO infrastructure.
Stockholders approved share issuance related to warrants; warrant expiration fixed to Dec 3, 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.